AR129053A1 - Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos - Google Patents
Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestosInfo
- Publication number
- AR129053A1 AR129053A1 ARP230100902A ARP230100902A AR129053A1 AR 129053 A1 AR129053 A1 AR 129053A1 AR P230100902 A ARP230100902 A AR P230100902A AR P230100902 A ARP230100902 A AR P230100902A AR 129053 A1 AR129053 A1 AR 129053A1
- Authority
- AR
- Argentina
- Prior art keywords
- membered
- c6alkyl
- cycloalkyl
- heterocyclic
- independently selected
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 102100036816 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Human genes 0.000 title 1
- 101000851788 Homo sapiens Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Proteins 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 22
- 125000001072 heteroaryl group Chemical group 0.000 abstract 21
- 125000000623 heterocyclic group Chemical group 0.000 abstract 21
- 125000003118 aryl group Chemical group 0.000 abstract 18
- 229910052739 hydrogen Inorganic materials 0.000 abstract 13
- 239000001257 hydrogen Substances 0.000 abstract 13
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical class 0.000 abstract 10
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 208000032839 leukemia Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- -1 C1-C6alkyl Chemical class 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En este documento se proporcionan compuestos que tienen la fórmula (1) para tratar, prevenir o controlar el cáncer. También se proporcionan composiciones farmacéuticas que comprenden los compuestos y métodos de uso de los compuestos y composiciones. En determinadas modalidades, los métodos abarcan el tratamiento, la prevención o el control del cáncer, incluidos los tumores sólidos y los tumores transmitidos por la sangre, utilizando los compuestos proporcionados en el presente documento. Reivindicación 1: Un compuesto que tiene una fórmula (1), una sal, solvato, hidrato, co-cristal, clatrato, polimorfo o tautómero farmacéuticamente aceptable del mismo, una sal farmacéuticamente aceptable del polimorfo o tautómero, un estereoisómero de cualquiera de los anteriores, o una mezcla de los mismos, en donde: A se selecciona independientemente de un cicloalquilo de 3 a 12 miembros sustituido o no sustituido, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros, o un anillo heteroarilo de 5 a 12 miembros; B se selecciona independientemente de un cicloalquilo de 3 a 12 miembros sustituido o no sustituido, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros o un anillo heteroarilo de 5 a 12 miembros; X se selecciona independientemente de O o -NR¹¹; R¹ se selecciona independientemente de hidrógeno, halógeno, alquilo-C₁-C₆ o un cicloalquilo de 3 a 6 miembros; R² se selecciona independientemente de hidrógeno, halógeno, -C(O), alquilo-C₁-C₆, un cicloalquilo de 3 a 6 miembros, en donde el alquilo o cicloalquilo se puede sustituir opcionalmente por -R¹¹, -N(R¹¹R¹¹), -NHR¹¹ o -OR¹¹; R³ se selecciona independientemente de hidrógeno, halógeno, -OR¹¹, -N(R¹¹R¹¹), -NHR¹¹, alquilo-C₁-C₆, un cicloalquilo de 3 a 6 miembros, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros o un anillo heteroarilo de 5 a 12 miembros, en donde el alquilo, cicloalquilo, heterocíclico y heteroarilo se pueden sustituir opcionalmente por -R¹¹, -N(R¹¹R¹¹), -NHR¹¹ o -OR¹¹; R⁴ se selecciona independientemente de hidrógeno, halógeno, alquilo-C₁-C₆, un cicloalquilo de 3 a 6 miembros, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros o un anillo heteroarilo de 5 a 12 miembros, en donde el alquilo, cicloalquilo, heterocíclico y heteroarilo se pueden sustituir opcionalmente por -R¹¹, -NHR¹¹ o -OR¹¹; R⁵ se selecciona independientemente de hidrógeno, alquilo-C₁-C₆, un cicloalquilo de 3 a 6 miembros, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros o un anillo heteroarilo de 5 a 12 miembros, en donde el alquilo, cicloalquilo, heterocíclico y heteroarilo se pueden sustituir opcionalmente por -R¹¹, -N(R¹¹R¹¹), -NHR¹¹ o -OR¹¹; R⁶ se selecciona independientemente de hidrógeno, alquilo-C₁-C₆, un cicloalquilo de 3 a 6 miembros, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros o un anillo heteroarilo de 5 a 12 miembros, en donde el alquilo, cicloalquilo, heterocíclico y heteroarilo se pueden sustituir opcionalmente por -R¹¹, -N(R¹¹R¹¹), -NHR¹¹ o -OR¹¹; en donde dos sustituyentes R⁵ y R⁶ junto a los átomos de carbono a los que se unen, pueden unirse para formar un anillo de 5 a 6 miembros que puede ser saturado, parcialmente saturado, y pueden ser opcionalmente sustituidos por 1 o 2 R¹¹ sustituyentes; R⁷ se selecciona independientemente de hidrógeno, halógeno, -OR¹¹, alquilo-C₁-C₆, -(haloalquilo C₁-C₆), -(alquilo C₁-C₆)-O-(alquilo C₁-C₆), -NHR¹¹, -N(R¹¹R¹¹), -CN, cicloalquilo de 3 a 12 miembros, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros o un anillo heteroarilo de 5 a 12 miembros, alquenilo-C₂-C₆, -O-(haloalquilo C₁-C₆)-O-(alquilo C₁-C₆), -C(=O)-(alquilo C₁-C₆), -C(=O)OH, -C(=O)-O-(alquilo C₁-C₆), -C(=O)NH₂, -C(=O)NH(R¹¹), -C(=O)N(R¹¹R¹¹), -S(O)₂R¹¹, -S(=O)R¹¹, -SR¹¹, -S(=O)₂NH₂, -S(=O)₂NH(alquilo C₁-C₆), o -S(=O)₂N(alquilo C₁-C₆)₂, en donde el alquilo, haloalquilo, cicloalquilo, heterocíclico, arilo, o heteroarilo se pueden sustituir opcionalmente por -R¹¹, -N(R¹¹R¹¹), -NHR¹¹ o -OR¹¹; R⁸ se selecciona independientemente de hidrógeno, halógeno o un alquilo-C₁-C₆, opcionalmente sustituido por -R¹¹, -N(R¹¹R¹¹), -NHR¹¹ o -OR¹¹; R⁹ se selecciona independientemente de hidrógeno, halógeno, -OR¹¹, alquilo-C₁-C₆, -(haloalquilo C₁-C₆), -(alquilo C₁-C₆)-O-(alquilo C₁-C₆), -NHR¹¹, -N(R¹¹R¹¹), -CN, cicloalquilo de 3 a 12 miembros, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros o un anillo heteroarilo de 5 a 12 miembros, alquenilo-C₂-C₆, -O-(haloalquilo C₁-C₆)-O-(alquilo C₁-C₆), -C(=O)-(alquilo C₁-C₆), -C(=O)OH, -C(=O)-O-(alquilo C₁-C₆), -C(=O)NH₂, -C(=O)NH(R¹¹), -C(=O)N(R¹¹R¹¹), -S(O)₂R¹¹, -S(=O)R¹¹, -SR¹¹, -S(=O)₂NH₂, -S(=O)₂NH(alquilo C₁-C₆), o S(=O)₂N(alquilo C₁-C₆)₂, en donde el alquilo, haloalquilo, cicloalquilo, heterocíclico, arilo, o heteroarilo se pueden sustituir opcionalmente por -R¹¹, -N(R¹¹R¹¹), -NHR¹¹ o -OR¹¹; R¹⁰ se selecciona independientemente de hidrógeno, halógeno, -OR¹¹, alquilo-C₁-C₆, -(haloalquilo C₁-C₆), -(alquilo C₁-C₆)-O-(alquilo C₁-C₆), -NHR¹¹, -N(R¹¹R¹¹), -CN, cicloalquilo de 3 a 12 miembros, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros o un anillo heteroarilo de 5 a 12 miembros, alquenilo-C₂-C₆, -O-(haloalquilo C₁-C₆)-O-(alquilo C₁-C₆), -C(=O)-(alquilo C₁-C₆), -C(=O)OH, -C(=O)-O-(alquilo C₁-C₆), -C(=O)NH₂, -C(=O)NH(R¹¹), -C(=O)N(R¹¹R¹¹), -S(O)₂R¹¹, -S(=O)R¹¹, -SR¹¹, -S(=O)₂NH₂, -S(=O)₂NH(alquilo C₁-C₆), o -S(=O)₂N(alquilo C₁-C₆)₂, en donde el alquilo, haloalquilo, cicloalquilo, heterocíclico, arilo, o heteroarilo se pueden sustituir opcionalmente por -R¹¹, -N(R¹¹R¹¹), -NHR¹¹ o -OR¹¹; R¹¹ se selecciona independientemente de hidrógeno, halógeno, alquilo-C₁-C₆, alquenilo-C₂-C₆, -haloalquilo C₁-C₆, un cicloalquilo de 3 a 12 miembros, heterocíclico de 4 a 12 miembros, arilo de 5 a 12 miembros o un anillo heteroarilo de 5 a 12 miembros; en donde el anillo alquilo, alquenilo, haloalquilo, cicloalquilo, heterocíclico, arilo o heteroarilo en R¹¹ son cada uno independientemente sustituidos o no sustituidos por 1, 2, o 3 R¹² sustituyentes; R¹² en cada caso se selecciona independientemente de hidrógeno, alquilo-C₁-C₆, halógeno, -OH, -O-(alquilo C₁-C₆)-, -NH₂, un alquilo de 3 a 12 miembros, heterocíclico de 5 a 12 miembros, arilo de 5 a 12 miembros o anillo heteroarilo de 5 a 12 miembros; en donde el anillo alquilo, alquenilo, haloalquilo, cicloalquilo, heterocíclico, arilo o heteroarilo en R¹² son cada uno independientemente sustituidos o no sustituidos por R¹³; R¹³ es independientemente hidrógeno, halo, alquilo-C₁-C₆, haloalquilo-C₁-C₆, alcoxialquilo-C₁-C₆, oxo, hidroxilo o alcoxi-C₁-C₆; y adicionalmente en donde dos sustituyentes R⁹ y R¹⁰ en átomos de carbono adyacentes del grupo A o B pueden unirse para formar un anillo de 5 a 6 miembros que puede ser saturado, parcialmente saturado, o aromático; y pueden ser opcionalmente sustituidos por 1 o 2 R¹³ sustituyentes y puede incluir un sustituyente oxo si el anillo no es un anillo aromático; en donde el anillo cíclico heterocíclico y heteroarilo en cada A, B, R³, R⁴, R⁵, R⁶, R⁷, R⁹, R¹⁰, R¹¹, R¹² y R¹³ puede incluir 1, 2 o 3 heteroátomos seleccionados independientemente de O, N o S. Reivindicación 23: El compuesto para uso según la reivindicación 22, en el que el cáncer es leucemia, en donde la leucemia es leucemia linfocítica crónica, leucemia mielocítica crónica, leucemia linfoblástica aguda o leucemia mieloide aguda.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263331193P | 2022-04-14 | 2022-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129053A1 true AR129053A1 (es) | 2024-07-10 |
Family
ID=86329395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100902A AR129053A1 (es) | 2022-04-14 | 2023-04-13 | Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12187699B2 (es) |
| EP (1) | EP4508044A1 (es) |
| JP (1) | JP2025513877A (es) |
| KR (1) | KR20250003774A (es) |
| CN (1) | CN119013266A (es) |
| AR (1) | AR129053A1 (es) |
| AU (1) | AU2023252917A1 (es) |
| CA (1) | CA3255290A1 (es) |
| IL (1) | IL316238A (es) |
| MX (1) | MX2024012493A (es) |
| TW (1) | TW202406901A (es) |
| WO (1) | WO2023201282A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085416A1 (en) * | 2023-10-16 | 2025-04-24 | Bristol-Myers Squibb Company | Gspt1 compounds and methods of use of the compounds |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2266629C (en) | 1996-10-01 | 2002-04-16 | Cima Labs Inc. | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ATE272394T1 (de) | 1996-10-31 | 2004-08-15 | Takeda Chemical Industries Ltd | Zubereitung mit verzögerter freisetzung |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| EP1048301A4 (en) | 1998-01-16 | 2005-03-09 | Takeda Chemical Industries Ltd | COMPOSITIONS WITH DELAYED ACTIVE INGREDIENTS, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| SG195613A1 (en) | 2008-10-29 | 2013-12-30 | Celgene Corp | Isoindoline compounds for use in the treatment of cancer |
| KR20180095094A (ko) * | 2016-01-08 | 2018-08-24 | 셀진 코포레이션 | 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도 |
| JP7724394B2 (ja) | 2019-10-09 | 2025-08-18 | モンテ ローザ セラピューティクス アーゲー | イソインドリノン化合物 |
| KR20220142393A (ko) * | 2021-04-14 | 2022-10-21 | 주식회사 레고켐 바이오사이언스 | 단백질 분해제 접합체 및 이의 용도 |
-
2023
- 2023-04-13 WO PCT/US2023/065699 patent/WO2023201282A1/en not_active Ceased
- 2023-04-13 EP EP23722242.7A patent/EP4508044A1/en active Pending
- 2023-04-13 JP JP2024560612A patent/JP2025513877A/ja active Pending
- 2023-04-13 IL IL316238A patent/IL316238A/en unknown
- 2023-04-13 KR KR1020247037485A patent/KR20250003774A/ko active Pending
- 2023-04-13 AU AU2023252917A patent/AU2023252917A1/en active Pending
- 2023-04-13 AR ARP230100902A patent/AR129053A1/es unknown
- 2023-04-13 US US18/300,315 patent/US12187699B2/en active Active
- 2023-04-13 CA CA3255290A patent/CA3255290A1/en active Pending
- 2023-04-13 TW TW112113868A patent/TW202406901A/zh unknown
- 2023-04-13 CN CN202380033869.3A patent/CN119013266A/zh active Pending
-
2024
- 2024-10-09 MX MX2024012493A patent/MX2024012493A/es unknown
- 2024-11-15 US US18/948,828 patent/US20250092012A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025513877A (ja) | 2025-04-30 |
| TW202406901A (zh) | 2024-02-16 |
| MX2024012493A (es) | 2024-11-08 |
| CN119013266A (zh) | 2024-11-22 |
| EP4508044A1 (en) | 2025-02-19 |
| WO2023201282A1 (en) | 2023-10-19 |
| IL316238A (en) | 2024-12-01 |
| KR20250003774A (ko) | 2025-01-07 |
| CA3255290A1 (en) | 2023-10-19 |
| US12187699B2 (en) | 2025-01-07 |
| AU2023252917A1 (en) | 2024-11-28 |
| US20230331693A1 (en) | 2023-10-19 |
| US20250092012A1 (en) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230824A1 (es) | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| AR118374A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| AR070513A1 (es) | Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20252677A1 (es) | Amidas de azolipiridina piridazinona como inhibidores de sos1 | |
| AR129053A1 (es) | Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos | |
| AR126612A1 (es) | Compuestos de heteroarilo para el tratamiento de la enfermedad de huntington | |
| PE20251586A1 (es) | Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos | |
| PE20250681A1 (es) | Compuestos heterociclicos y metodos de uso | |
| AR127355A1 (es) | Moduladores de micromoléculas de la actividad de la glucocerebrosidasa y usos de estos | |
| AR044470A1 (es) | Derivados de pirrol sustituidos | |
| AR126048A1 (es) | Derivados heterocíclicos condensados | |
| AR120324A1 (es) | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica | |
| AR114167A1 (es) | Derivados de 2-ciclopropansulfonamidopirimidina como inhibidores de ctps1 | |
| AR129523A1 (es) | Inhibidores de cgas | |
| MX2021008386A (es) | Compuesto interno de sulfiamidina amida-aril amida cíclica y su uso para el tratamiento de la hepatitis b. | |
| AR129089A1 (es) | Inhibidores de kit | |
| AR128323A1 (es) | Inhibidores de parp7 | |
| AR127854A1 (es) | Inhibidores de las quinasas gcn2 y perk y métodos de uso de los mismos | |
| AR118362A1 (es) | Inhibición de la proteína de unión al elemento de respuesta a amp cíclico (creb) | |
| AR119297A1 (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| AR130836A1 (es) | Nuevos compuestos heterocíclicos | |
| AR131074A1 (es) | Compuestos inhibidores de malt1 |